Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bcg vaccine (Statens Bakteriologiska Laboratorium)
- Development stage
- Unknown
- Lead developer
- Valneva
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravesical
01
Overview
BCG-Sweden is a specific live-attenuated strain of *Mycobacterium bovis* used as a vaccine for the prevention of tuberculosis and as an intravesical immunotherapy for non-muscle invasive bladder cancer. It belongs to the "late" genetic cluster of BCG strains, characterized by specific genomic differences such as the DU2 duplication. Like other BCG strains, BCG-Sweden confers protection not only against tuberculosis but also persistent nonspecific protection against diverse diseases through a mechanism known as "trained immunity." This process involves the epigenetic and metabolic reprogramming of innate immune cells, specifically mediated by the Akt-mTOR-HIF1α signaling axis and NOD-like receptor signaling. Research indicates that BCG-Sweden's ability to induce trained immunity is correlated with linoleic acid metabolism, which may act as an adjuvant to enhance these nonspecific protective effects.
- Other names
- BCG-SwedenBCG Swedish strainBCG Gothenburg strainBCG GothenburgBacillus Calmette-Guérin vaccine
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)HIF1A (Hypoxia-inducible factor 1-alpha)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on bcg vaccine (Statens Bakteriologiska Laboratorium).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bcg vaccine (Statens Bakteriologiska Laboratorium).